Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors

Completed

Conditions studied: Breast Cancer

In brief

The investigators are hypothesizing that decreasing estrogen levels will cause serum DKK1 to peak, then decrease gradually as estrogens reach a new lower, but steady level. The investigators also believe that the peak in DKK1 will initiated a wave of stem cell diversion from the osteoblastogenic pathway to the adipogenic pathway. The investigators will conduct a longitudinal cohort study of post menopausal women with hormone-responsive breast cancer that will be treated AIs. The study will observe anthromorphic and serum marker changes during the first year of their treatment.

Key facts

Study ID

NCT01431872

Run by

University of Arkansas

People needed

17

Starts

2011-04-01

Expected to finish

2015-08-01

Last updated by the study team

2015-11-04

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Post Menopausal Breast cancer patients with planned treatment of aromatase inhibitors.
• 18 years or older

You may not qualify if…

• BMI >30 or <18
• Osteoporosis as defined by protocol.
• Subjects currently on bisphosphonate therapy.
• History of primary or secondary hyperparathyroidism
• History of Hypo-or Hyperthyroidism
• History of Vitamin D levels below LLN
• History of creatinine clearance below the EGFR
• History ofLiver function tests above 1.5 times ULN including LDH, SGOT, SGPT, Alkaline phosphatase, and Bilirubin
• History of documented cirrhosis of the liver
• History of chronic heparin use
• History of chronic glucocorticoid therapy

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.